Ambu's Q3 ended better than expected

After a downgrade earlier in the year, pessimism had grown regarding Ambu's third quarter, though it turned out to go slightly above expectations. The launch of one of the firm's new products is postponed, however.

Photo: PR / Ambu

The third-quarter financials of Danish medical technology firm Ambu ended up slightly better than expected earlier this year after the company presented preliminary figures in connection with a downgrade.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs